U.S., April 10 -- ClinicalTrials.gov registry received information related to the study (NCT07520045) titled 'Biomarkers in Diabetic Retinopathy Treated With Faricimab vs Biosimilar Ranibizumab' on April 02.
Brief Summary: The goal of this clinical trial is to see if treatment with faricimab or biosimilar ranibizumab leads to different early imaging changes in adults with diabetic retinopathy requiring anti-VEGF treatment and to identify OCT and OCTA biomarkers predictive of differential early treatment response between the two therapies. The main questions it aims to answer are:
Which OCT and OCT angiography biomarkers predict early treatment response? How do imaging biomarkers change after three loading doses of treatment? Are imaging b...